Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Quanterix ( (QTRX) ) has provided an update.
On January 8, 2026, Quanterix announced a planned leadership transition under which Everett Cunningham will become President and Chief Executive Officer and join the board on January 19, 2026, succeeding Masoud Toloue, who will step down as CEO, resign from the board and remain in an advisory role during the handover. The board highlighted Toloue’s role in expanding the assay menu, entering adjacent markets, building the diagnostics business and completing the acquisition of Akoya Biosciences, and framed Cunningham’s appointment—backed by a substantial mix of time- and performance-based equity tied to ambitious share-price hurdles—as a move to accelerate commercial execution and growth. Cunningham, a veteran commercial leader from Illumina, Exact Sciences, GE Healthcare, Quest Diagnostics and Pfizer, is being brought in as Quanterix disclosed that it expects to exceed its revenue and cash guidance for full-year 2025, signaling confidence in the company’s operational trajectory and reinforcing its ambition to scale its integrated biomarker and spatial biology platform for broader scientific and clinical impact.
The most recent analyst rating on (QTRX) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Quanterix stock, see the QTRX Stock Forecast page.
Spark’s Take on QTRX Stock
According to Spark, TipRanks’ AI Analyst, QTRX is a Neutral.
Quanterix’s overall stock score reflects a mix of significant financial challenges and positive technical and strategic developments. The company’s financial performance is a major concern, with negative profitability and cash flow issues. However, positive technical indicators and strategic corporate events provide some optimism. The earnings call suggests potential for future growth, but valuation remains a concern due to ongoing losses.
To see Spark’s full report on QTRX stock, click here.
More about Quanterix
Quanterix is a global leader in ultra-sensitive biomarker detection, providing its proprietary Simoa technology to enable disease research, diagnostics and drug development with blood and other fluid-based assays. Following its 2025 acquisition of Akoya Biosciences, the spatial biology company, Quanterix now offers an integrated platform that combines ultra-sensitive liquid biomarker measurement with multiplexed tissue imaging at single-cell resolution, strengthening its position in precision medicine by connecting biological insights across blood and tissue for academic, biopharma and clinical customers.
Average Trading Volume: 650,986
Technical Sentiment Signal: Sell
Current Market Cap: $306M
See more insights into QTRX stock on TipRanks’ Stock Analysis page.